tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Mayank Mamtani, 251 are a BUY (89.01%), 29 are a HOLD (10.28%), 2 are a SELL (0.71%).
Analyst Mayank Mamtani, currently employed at B. RILEY, carries an average stock price target met ratio of 30.71% that have a potential upside of 53.61% achieved within 119 days.
Mayank Mamtani’s has documented 567 price targets and ratings displayed on 45 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NKTR, Nektar Therapeutics at 23-Feb-2026.
Analyst best performing recommendations are on ARQL (ARQULE).
The best stock recommendation documented was for ALT (ALTIMMUNE) at 11/9/2023. The price target of $8 was fulfilled within 39 days with a profit of $5.55 (226.53%) receiving and performance score of 58.08.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 12-Jul-2023
$12
$8.63 (256.08%)
$12
1 years 5 months 14 days ago
(26-Sep-2024)
0/2 (0%)
$8.93 (290.88%)
Buy
$2.5
$-0.28 (-10.07%)
3 years 25 days ago
(15-Feb-2023)
1/1 (100%)
$1.86 (290.63%)
145
Buy Since 15-Feb-2022
$30
3 years 8 months 18 days ago
(22-Jun-2022)
0/1 (0%)
$22.32 (290.63%)
Hold Since 02-Sep-2020
$12
$8.63 (256.08%)
5 years 6 months 10 days ago
(02-Sep-2020)
1/2 (50%)
$1.58 (15.16%)
19
Buy Since 31-Aug-2020
5 years 6 months 9 days ago
(31-Aug-2020)
0/1 (0%)
$59.52 (163.16%)
Which stock is Mayank Mamtani is most bullish on?
Which stock is Mayank Mamtani is most reserved on?
What Year was the first public recommendation made by Mayank Mamtani?
